Screener
Ligand Pharmaceuticals LGND Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current liabilities | 955 | 135 |
| Total current liabilities | 46,736 | 37,447 |
| Long-term contingent liabilities | 2,382 | 2,934 |
| Long-term operating lease liabilities | 3,777 | 4,204 |
| Convertible senior notes, net | 1,126,594 | 446,192 |
| Deferred income taxes, net | 21,654 | 36,019 |
| Other long-term liabilities | 17,216 | 16,629 |
| Total liabilities | 1,218,359 | 543,425 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's operating lease liabilities?
- Ligand Pharmaceuticals (LGND) reported operating lease liabilities of $3.78M in Q2 2026.
- How has Ligand Pharmaceuticals's operating lease liabilities changed year-over-year?
- Ligand Pharmaceuticals's operating lease liabilities decreased by 18.4% year-over-year, from $4.63M to $3.78M.
- What is the long-term trend for Ligand Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's operating lease liabilities has grown at a -5.7% compound annual growth rate (CAGR), from $5.64M to $4.2M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Ligand Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude